BioNTech’s €16.8 Billion War Chest Funds a Cancer Pipeline That the Market Is Treating as a Side Bet

Despite founder exit and revenue drop, BioNTech's €16.8B cash and 15 Phase 3 cancer trials make its stock undervalued; UBS upgrades to Buy.

BioNTech is sitting on €16.8 billion in cash, running 15 late-stage cancer trials, and has just watched its own founders decide to walk away. The stock is hovering around €80, more than 26% below its 52?week high of €105.80, and low enough that stripping out the cash pile values the entire oncology pipeline at only a few billion euros. For investors willing to look past the short-term noise, that arithmetic is beginning to look absurd.

The departure of Ugur Sahin and Özlem Türeci at the end of 2026 is the most dramatic signal yet that BioNTech is closing the Covid chapter for good. The pair plan to launch an independent mRNA start?up, with BioNTech contributing licences in exchange for a minority stake. The move lets both entities focus on their own priorities, but it also forces a leadership handover at a critical moment. The search for successors is already under way, and a smooth transition will be essential if the company is to keep its ambitious oncology timeline on track.

That timeline is packed. By December, BioNTech expects to have 15 parallel Phase?3 studies running, with seven major data readouts still due. The two lead assets are the antibody Gotistobart and the immunomodulator Pumitamig, the latter developed jointly with Bristol Myers Squibb. At the ASCO conference, Pumitamig showed promising anti?tumour activity in the ROSETTA?Lung?02 trial for first?line lung cancer, while Gotistobart delivered durable survival benefits in platinum?resistant ovarian cancer. The market’s reaction was muted, but analysts argue that only final late?stage results will count as real catalysts.

The second half of the year is loaded with potential triggers. BioNTech plans to start six more Phase?3 trials, bringing the total to 15. Data for Trastuzumab Pamirtecan in endometrial cancer are expected, and the company intends to file a US approval application for that asset before year?end. Every positive readout should chip away at the deep scepticism that has kept the stock pinned down.

That scepticism is rooted in near?term finances. First?quarter revenue collapsed to €118.1 million, while the net loss widened to €531.9 million. R&D spending surged to €557 million as BioNTech prepares its first oncology launches. Management has held its full?year guidance of €2.0?billion to €2.3?billion in revenue, but that still represents a further decline from the Covid?era peak. For investors accustomed to the billions of euros that flowed during the pandemic, the transition is painful.

Yet the financial backbone remains formidable. With €16.8?billion in liquid assets, BioNTech can fund its transformation without strain. A $1?billion share buy?back programme, announced alongside the quarterly figures, underscores management’s confidence. At the current market capitalisation of roughly €19.7?billion, subtracting the cash leaves the entire pipeline valued at a fraction of its potential.

UBS was among the first to act, upgrading the stock to Buy shortly before ASCO and setting a price target of $135. The consensus analyst target stands at €106.71, implying a 37% upside from current levels. Not a single analyst rates the stock a Sell – a remarkable show of unanimity for a volatile biotech name.

The bull case is essentially a bet on time. With 13 registration?enabling studies under way and a cash cushion that can withstand years of losses, the market is pricing in a scenario where everything goes wrong. The data do not support that pessimism. Delays remain a real risk, and the shrinking vaccine revenue stream will continue to weigh on the income statement. But at €80 – just 14% above the 52?week low – the downside appears limited, while a breakthrough in lung cancer could send the shares sharply higher. BioNTech is reinventing itself under new leadership, and the market may soon have to catch up.